Name (Synonyms) | Correlation | |
---|---|---|
drug195 | CAStem Wiki | 1.00 |
drug83 | Ascorbic Acid Wiki | 0.50 |
drug522 | Hydroxychloroquine Sulfate Wiki | 0.30 |
drug108 | Azithromycin Wiki | 0.19 |
Name (Synonyms) | Correlation | |
---|---|---|
D055370 | Lung Injury NIH | 0.25 |
D011024 | Pneumonia, Viral NIH | 0.14 |
D013577 | Syndrome NIH | 0.13 |
D055371 | Acute Lung Injury NIH | 0.13 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.13 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.11 |
D011014 | Pneumonia NIH | 0.07 |
There is one clinical trial.
This is a randomized trial for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in high-risk adults not requiring hospital admission.The overarching goal of this study is to assess the effectiveness of interventions on the incidence of lower respiratory tract infection (LRTI) progression among high-risk adult outpatients with SARS-CoV-2 infection to inform public health control strategies.
Description: Resting blood oxygen saturation (SpO2<93%) level sustained for 2 readings 2 hours apart and presence of subjective dyspnea or cough
Measure: Lower respiratory tract infection (LRTI) rates Time: 28 days from enrolmentDescription: Cumulative incidence of hospitalization or mortality
Measure: Incidence of hospitalization or mortality Time: Day 28 after enrolmentDescription: Time to clearance of nasal SARS-CoV-2, defined as 2 consecutive negative swabs
Measure: Change in upper respiratory viral shedding Time: Day 1 through Day 14 after enrolmentDescription: Serious adverse events (including death and hospitalization) and adverse events resulting in treatment discontinuation
Measure: Rate of participant-reported adverse events Time: 28 days from enrolment